With his sizzling fastball clocking 99 mph and long, blond locks dangling down his neck, Syndergaard held San Francisco hitless until Denard Span's two-out single in the sixth.
With his sizzling fastball clocking 99 mph and long, blond locks dangling down his neck, Syndergaard held San Francisco hitless until Denard Span's two-out single in the sixth. .
Osmotic, controlled-release (OROS) MPH, a long-acting MPH formulation, uses OROS® (osmotic release oral system) technology to produce an ascending MPH plasma profile [ 13].
Both clinical and preclinical studies converge to confirm that in subjects suffering from cognitive-motivational and neural impairments, MPH has long-term beneficial effects in several respects, e.g. by reducing the core symptoms of ADHD as well as the risk for substance abuse [e.g. [ 102, 103, 115].
For patients achieving significant but suboptimal effects with a long-acting MPH medication, switching to another MPH formulation should be considered.
Clinicians are often uncertain about correct dosing when switching patients from immediate- or extended-release MPH to a long-acting MPH formulation with an immediate-release component of <50% (Concerta® in particular).
In head-to-head studies of Concerta® with five long-acting MPH formulations, Concerta® generally reached peak plasma MPH concentration later (5 8 hours post-dose) than the other long-acting MPH formulations investigated (Ritalin LA®, Biphentin®, Ritalin SR® and Equasym XL®; 4 6 hours post-dose) with the exception of Daytrana® which reached peak levels 10 hours post-dose (Table 3) [ 20, 22- 25].
For patients achieving suboptimal symptom control, switching long-acting MPH formulations may be beneficial.
Three studies assessed the bioequivalence of long-acting MPH formulations with Concerta®[ 20, 22, 25].
Therefore, this provides head-to-head comparisons of Concerta® with five long-acting MPH formulations.
